Browse News
Filter News
Found 19 articles
-
Kelonia Therapeutics’ in vivo gene placement system is being tapped to help Astellas Pharma expand its portfolio of in vivo CAR-T cell therapies for cancer.
-
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
2/15/2024
Astellas Pharma Inc. and Kelonia Therapeutics announced that Xyphos Biosciences, Inc., and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.
-
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
11/30/2023
Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).
-
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
3/30/2023
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., “Astellas”).
-
PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
3/6/2023
Phanes Therapeutics, Inc. today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company.
-
Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.
-
Astellas Unveils Plans to Open New Biotech Campus in South San Francisco
7/22/2022
Astellas Pharma Inc. announced plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center.
-
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
-
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
6/1/2022
Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.
-
AbSci Enters Biologics Development Collaboration with Xyphos Biosciences, an Astellas Company
2/3/2021
AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced that it has partnered with Xyphos Biosciences, an Astellas Company, to screen and identify a variant of Xyphos' MicAbody™ lead candidate for optimal manufacturing cell line development.
-
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.
-
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
12/26/2019
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton, "Xyphos") today announced that Astellas has acquired Xyphos.
-
Gladstone Investigators and Xyphos Partner to Successfully Adapt CAR-T Immunotherapy to Target the HIV Latent Reservoir
10/24/2019
Gladstone researchers Warner C. Greene and Eytan Herzig collaborated with Xyphos Biosciences, Inc., to develop a novel immunotherapy for HIV.
-
Xyphos Biosciences and Gladstone Institutes Announce Publication Demonstrating convertibleCAR® Cells and Bispecific Broadly Neutralizing Antibodies Reduce Latent HIV Reservoir
10/24/2019
Xyphos Biosciences, Inc. and Gladstone Institutes today announced the publication of key preclinical data demonstrating that convertibleCAR® cells attack and significantly reduce latent reservoirs of diverse HIV strains
-
Key Patent Issued for Xyphos Biosciences' ACCEL™ Technology Platform
4/16/2019
Patent Protects Xyphos' Advanced Cell-based Cancer Therapies
-
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
4/1/2019
Knight is failing, its CEO and Board are conflicted and shareholders are suffering as a result
-
The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
10/18/2018
The Parker Institute for Cancer Immunotherapy and Xyphos Biosciences today announced a collaboration to create universal CAR-T therapies to treat multiple cancer types using the company's 'convertibleCAR'® platform.
-
Xyphos Biosciences Names Thorsten Melcher, Ph.D., as Chief Business Officer
7/2/2018
Dr. Melcher will lead all business development and financing activities, including implementing strategic collaboration and licensing arrangements for Xyphos’ ACCEL™ platform and its derived cell therapy products.
-
AvidBiotics is splitting into two separate companies and has developed two separate but similar technology platforms.